Metastatic Castrate Resistant Prostate Cancer (mCRPC) Clinical Trials in Beijing, Beijing Municipality

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).